

Eva Kubala Havrdova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6961707/eva-kubala-havrdova-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 282 papers | 23,818 citations | 64 h-index | 151 g-index |
| 319 ext. papers | 27,733 ext. citations | 7.3 avg, IF | 6.23 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 282 | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302 | 9.4 | 6480 |
| 281 | A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 354, 899-910 | 59.2 | 2432 |
| 280 | Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 367, 1087-97 | 59.2 | 943 |
| 279 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1819-28 | 40 | 834 |
| 278 | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39 | 40 | 827 |
| 277 | Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , 2008 , 372, 1463-72 | 42 | 398 |
| 276 | Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology, The</i> , 2009 , 8, 254-60 | 24.1 | 348 |
| 275 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120 | 5 | 286 |
| 274 | The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. <i>Neurology</i> , 2007 , 69, 1391-403 | 6.5 | 263 |
| 273 | MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. <i>Neurology</i> , 2007 , 68, 1390-401 | 6.5 | 260 |
| 272 | Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 381, 2167-75 | 40 | 236 |
| 271 | Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , 2008 , 371, 2085-92 | 40 | 236 |
| 270 | Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology, The</i> , 2011 , 10, 745-58 | 24.1 | 212 |
| 269 | Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015 , 373, 1418-28 | 59.2 | 203 |
| 268 | Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. <i>Neurology</i> , 2014 , 82, 573-81 | 6.5 | 200 |
| 267 | Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , 2016 , 15, 574-84 | 24.1 | 194 |
| 266 | Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. <i>Lancet Neurology, The</i> , 2009 , 8, 1111-9 | 24.1 | 192 |

| | | | |
|-----|---|------|-----|
| 265 | Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 143-52 | 5 | 186 |
| 264 | Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24 | 5 | 181 |
| 263 | Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. <i>Journal of Neurology</i> , 2002 , 249, 1088-97 | 5.5 | 181 |
| 262 | Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126 | 6.5 | 175 |
| 261 | Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. <i>Journal of Neurology</i> , 2008 , 255, 1449-63 | 5.5 | 173 |
| 260 | Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 814-23 | 5 | 173 |
| 259 | Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405 | 11.2 | 172 |
| 258 | Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187 | 27.4 | 172 |
| 257 | The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009 , 256, 405-15 | 5.5 | 164 |
| 256 | Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , 2007 , 6, 431-41 | 24.1 | 161 |
| 255 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , 2018 , 17, 405-415 | 24.1 | 150 |
| 254 | Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017 , 74, 459-469 | 17.2 | 147 |
| 253 | Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 611-20 | 9.4 | 143 |
| 252 | Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116 | 6.5 | 139 |
| 251 | A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 773-83 | 5.5 | 136 |
| 250 | Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007 , 62, 335-46 | 9.4 | 136 |
| 249 | Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , 2012 , 11, 420-8 | 24.1 | 128 |
| 248 | Thalamic atrophy is associated with development of clinically definite multiple sclerosis. <i>Radiology</i> , 2013 , 268, 831-41 | 20.5 | 119 |

| | | | |
|-----|--|------|-----|
| 247 | Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 77, 425-35 | 9.4 | 118 |
| 246 | Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 89-100 | 9.4 | 117 |
| 245 | Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2012 , 33, 1573-8 | 4.4 | 112 |
| 244 | Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. <i>Journal of Neurology</i> , 2016 , 263, 1287-95 | 5.5 | 109 |
| 243 | Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3287-98 | 11.2 | 107 |
| 242 | Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. <i>Neurology</i> , 2007 , 68, 1299-304 | 30.4 | 107 |
| 241 | Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 253-265 | 5 | 105 |
| 240 | Freedom from disease activity in multiple sclerosis. <i>Neurology</i> , 2010 , 74 Suppl 3, S3-7 | 6.5 | 105 |
| 239 | Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281 | 24.1 | 101 |
| 238 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033 | 24.1 | 98 |
| 237 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1009-1020 | 24.1 | 96 |
| 236 | ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237 | 6 | 96 |
| 235 | Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. <i>Therapeutic Advances in Neurological Disorders</i> , 2015 , 8, 31-45 | 6.6 | 96 |
| 234 | "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1179-1187 | 5 | 90 |
| 233 | Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Clinical Neuropsychologist</i> , 2012 , 26, 1186-200 | 4.4 | 88 |
| 232 | Lipid profiles are associated with lesion formation over 24 months in interferon-β-treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1186-91 | 5.5 | 87 |
| 231 | Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13 | 17.2 | 83 |
| 230 | Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316 | 24.1 | 77 |

| | | | |
|-----|--|------|----|
| 229 | Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology, The</i> , 2014 , 13, 472-81 | 24.1 | 77 |
| 228 | Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , 2017 , 16, 658-665 | 13.6 | 76 |
| 227 | High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. <i>Bone Marrow Transplantation</i> , 2000 , 25, 525-31 | 4.4 | 74 |
| 226 | Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. <i>Archives of Neurology</i> , 2006 , 63, 614-9 | | 73 |
| 225 | Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018 , 141, 1085-1093 | 11.2 | 72 |
| 224 | Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. <i>Journal of the Neurological Sciences</i> , 2009 , 282, 112-9 | 3.2 | 69 |
| 223 | Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. <i>American Journal of Neuroradiology</i> , 2013 , 34, 1931-9 | 4.4 | 68 |
| 222 | Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 965-76 | 5 | 67 |
| 221 | Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 227-34 | | 67 |
| 220 | Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 126-9 | 5.5 | 66 |
| 219 | Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 19, 153-160 | 4 | 66 |
| 218 | High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 685-93 | 5 | 64 |
| 217 | Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 407-14 | 5.5 | 64 |
| 216 | Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 202-18 | 4 | 62 |
| 215 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443 | 11.2 | 62 |
| 214 | Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. <i>Clinical and Experimental Immunology</i> , 2015 , 181, 385-400 | 6.2 | 62 |
| 213 | Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , 2015 , 4, 93-104 | 4.6 | 62 |
| 212 | Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. <i>PLoS ONE</i> , 2012 , 7, e50101 | 3.7 | 62 |

| | | | |
|-----|--|-----|----|
| 211 | Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 314-21 | 5 | 57 |
| 210 | The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105 | 5 | 56 |
| 209 | A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1709-1718 | 5 | 54 |
| 208 | Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012 , 259, 898-905 | 5.5 | 54 |
| 207 | Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. <i>Current Medical Research and Opinion</i> , 2014 , 30, 613-27 | 2.5 | 53 |
| 206 | Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1360-6 | 5 | 52 |
| 205 | Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , 2013 , 260, 2286-96 | 5.5 | 50 |
| 204 | Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. <i>PLoS ONE</i> , 2013 , 8, e53996 | 3.7 | 50 |
| 203 | Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015 , 84, 1145-52 | 6.5 | 47 |
| 202 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 458-468 | 5.5 | 46 |
| 201 | Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617 | 5 | 46 |
| 200 | Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , 2016 , 6, e00518 | 3.4 | 45 |
| 199 | Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37 | 5.5 | 45 |
| 198 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1343-1349 | 5.5 | 44 |
| 197 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203 | 5.5 | 43 |
| 196 | Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5). <i>Journal of NeuroEngineering and Rehabilitation</i> , 2015 , 12, 14 | 5.3 | 43 |
| 195 | BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2011 , 258, 449-56 | 5.5 | 41 |
| 194 | A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , 2006 , 13, 61-71 | 6 | 41 |

| | | | |
|-----|---|------|----|
| 193 | Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. <i>Journal of Autoimmunity</i> , 2000 , 15, 441-9 | 15.5 | 41 |
| 192 | Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018 , 17, 444-451 | 5.3 | 41 |
| 191 | Complement activation in patients with neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2014 , 274, 185-91 | 3.5 | 40 |
| 190 | Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015 , 17, 236-43 | 2.3 | 40 |
| 189 | Infusion-related hypersensitivity reactions during natalizumab treatment. <i>Neurology</i> , 2006 , 67, 1717-8 | 6.5 | 39 |
| 188 | Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 558-567 | 17.2 | 39 |
| 187 | Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. <i>European Journal of Neurology</i> , 2017 , 24, 726-733 | 6 | 38 |
| 186 | Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , 2014 , 261, 1735-44 | 5.5 | 38 |
| 185 | The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. <i>JAMA Neurology</i> , 2014 , 71, 1386-93 | 17.2 | 38 |
| 184 | Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992 | 6.5 | 38 |
| 183 | Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 253-7 | 5 | 36 |
| 182 | Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016 , 16, 117 | 3.1 | 34 |
| 181 | Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015 , 56, 2010-8 | 6.3 | 33 |
| 180 | Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. <i>Sleep Medicine</i> , 2012 , 13, 848-51 | 4.6 | 33 |
| 179 | Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 513-9 | 4 | 32 |
| 178 | Hidden factors influencing quality of life in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22 Suppl 2, 28-33 | 6 | 32 |
| 177 | MRI correlates of disability progression in patients with CIS over 48 months. <i>NeuroImage: Clinical</i> , 2014 , 6, 312-9 | 5.3 | 32 |
| 176 | Cost of multiple sclerosis in the Czech Republic: the COMS study. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 662-8 | 5 | 32 |

| | | | |
|-----|---|-----|----|
| 175 | Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 51-61 | 5 | 31 |
| 174 | Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017 , 89, 1050-1059 | 6.5 | 31 |
| 173 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32 | 5 | 30 |
| 172 | Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 242-252 | 5 | 30 |
| 171 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71 | 5 | 30 |
| 170 | Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. <i>PLoS ONE</i> , 2012 , 7, e38661 | 3.7 | 29 |
| 169 | Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. <i>N Engl J Med</i> 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. <i>Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology</i> , 2017 , 24, 516-522 | 4 | 28 |
| 168 | Survey of diagnostic and treatment practices for multiple sclerosis in Europe. <i>European Journal of Neurology</i> , 2017 , 24, 516-522 | 6 | 27 |
| 167 | Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 859-64 | 5.5 | 27 |
| 166 | Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017 , 15, 769-779 | 5.3 | 27 |
| 165 | Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. <i>Physiological Research</i> , 2008 , 57, 151-164 | 2.1 | 27 |
| 164 | Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 79-90 | 5 | 27 |
| 163 | Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 770-81 | 5 | 26 |
| 162 | Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014 , 83, 1210-6 | 6.5 | 26 |
| 161 | Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. <i>European Neurology</i> , 2012 , 68, 23-7 | 2.1 | 26 |
| 160 | Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. <i>Clinical Rehabilitation</i> , 2005 , 19, 170-81 | 3.3 | 26 |
| 159 | Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. <i>Transplantation Proceedings</i> , 2001 , 33, 2179-81 | 1.1 | 26 |
| 158 | Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262 | 5 | 24 |

| | | | |
|-----|--|-----|----|
| 157 | Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 213-21 | 5 | 24 |
| 156 | Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 220-231 | 5 | 24 |
| 155 | Serum lipid profile changes predict neurodegeneration in interferon- β -treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017 , 58, 403-411 | 6.3 | 23 |
| 154 | Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1273-1288 | 5 | 23 |
| 153 | BREMSO: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 981-9 | 6 | 23 |
| 152 | Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 464-70 | 5 | 23 |
| 151 | Treatment optimization in multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , 2004 , 11, 43-7 | 6 | 23 |
| 150 | Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276 | 5 | 22 |
| 149 | Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β 1a. <i>European Journal of Neurology</i> , 2015 , 22, 1113-23 | 6 | 22 |
| 148 | Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , 2013 , 260, 462-9 | 5.5 | 22 |
| 147 | Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. <i>International Review of Neurobiology</i> , 2007 , 79, 475-89 | 4.4 | 22 |
| 146 | Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. <i>Clinica Chimica Acta</i> , 2004 , 348, 147-54 | 6.2 | 22 |
| 145 | Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. <i>Archives of Neurology</i> , 2005 , 62, 1519-30 | | 22 |
| 144 | Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 235-243 | 4 | 22 |
| 143 | Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 541-553 | 5 | 22 |
| 142 | Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1617-1626 | 5 | 21 |
| 141 | Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β 1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472 | 6.5 | 21 |
| 140 | Early predictors of non-response to interferon in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, 390-7 | 3.8 | 21 |

| | | | |
|-----|--|------|----|
| 139 | Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1367-1376 | 5.76 | 21 |
| 138 | Comparative efficacy of first-line natalizumab vs IFN-βr glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115 | 1.7 | 21 |
| 137 | Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , 2017 , 24, 292-301 | 6 | 20 |
| 136 | Risks of immune system treatments. <i>Science</i> , 2010 , 328, 825-6 | 33.3 | 20 |
| 135 | No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318760642 | 2 | 19 |
| 134 | The potential of serum neurofilament as biomarker for multiple sclerosis. <i>Brain</i> , 2021 , 144, 2954-2963 | 11.2 | 19 |
| 133 | Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 729-36 | 6 | 19 |
| 132 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652 | 5 | 18 |
| 131 | Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021 , 96, e783-e797 | 6.5 | 18 |
| 130 | Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 1423-1437 | 2.9 | 17 |
| 129 | Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 81-91 | 5.3 | 17 |
| 128 | How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?. <i>Frontiers in Neurology</i> , 2013 , 4, 10 | 4.1 | 17 |
| 127 | A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. <i>Journal of Neuroimaging</i> , 2017 , 27, 620-629 | 2.8 | 16 |
| 126 | Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. <i>Journal of Neuroimmunology</i> , 2014 , 273, 58-64 | 3.5 | 16 |
| 125 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. <i>Clinical Neurology and Neurosurgery</i> , 2012 , 114, 940-6 | 2 | 16 |
| 124 | Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7, | 9.1 | 16 |
| 123 | No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1736-1747 | 5 | 15 |
| 122 | Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018 , 18, 494-501 | 5.3 | 15 |

| | | | |
|-----|--|------|----|
| 121 | Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 19, 105-108 | 4 | 15 |
| 120 | Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 316-23 | 5.5 | 15 |
| 119 | Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101868 | 4 | 15 |
| 118 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369 | 5 | 14 |
| 117 | Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. <i>Genes and Immunity</i> , 2013 , 14, 244-8 | 4.4 | 14 |
| 116 | Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020 , 143, 1400-1413 | 11.2 | 13 |
| 115 | Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. <i>Neurology and Therapy</i> , 2016 , 5, 169-182 | 4.6 | 13 |
| 114 | Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 143, 424-33 | 5.1 | 13 |
| 113 | Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1346-1357 | 5 | 13 |
| 112 | Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348 | 11.6 | 13 |
| 111 | Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFN- β <i>Frontiers in Immunology</i> , 2020 , 11, 1527 | 8.4 | 13 |
| 110 | Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 6, 66-72 | 4 | 13 |
| 109 | The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus. <i>Neuroendocrinology Letters</i> , 2015 , 36, 564-71 | 0.3 | 13 |
| 108 | A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2019 , 40, 446-452 | 4.4 | 12 |
| 107 | Management of multiple sclerosis patients in central European countries: current needs and potential solutions. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418759189 | 6.6 | 12 |
| 106 | New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 41-52 | 5 | 12 |
| 105 | Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 11-19 | 4 | 12 |
| 104 | Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 624-32 | 6 | 11 |

| | | | |
|-----|---|------|----|
| 103 | Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5). <i>European Neurology</i> , 2016 , 76, 99-104 | 2.1 | 11 |
| 102 | Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. <i>JAMA Neurology</i> , 2013 , 70, 248-51 | 17.2 | 11 |
| 101 | Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. <i>European Journal of Neurology</i> , 2015 , 22, 570-7 | 6 | 11 |
| 100 | Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. <i>Wiener Medizinische Wochenschrift</i> , 2012 , 162, 354-66 | 2.9 | 11 |
| 99 | Monocyte NOTCH2 expression predicts IFN- γ immunogenicity in multiple sclerosis patients. <i>JCI Insight</i> , 2018 , 3, | 9.9 | 11 |
| 98 | Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020 , 77, 1496-1503 | 17.2 | 11 |
| 97 | Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 52-60 | 5 | 11 |
| 96 | Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286420982134 | 6.6 | 11 |
| 95 | Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013 , 263, 121-7 | 3.5 | 10 |
| 94 | HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011 , 236, 76-80 | 3.5 | 10 |
| 93 | Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 11, 18-24 | 4 | 9 |
| 92 | Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. <i>Journal of Clinical Neuroscience</i> , 2019 , 65, 28-33 | 2.2 | 9 |
| 91 | Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , 2015 , 36, 1457-64 | 4.4 | 9 |
| 90 | Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). <i>CNS Neuroscience and Therapeutics</i> , 2013 , 19, 302-6 | 6.8 | 9 |
| 89 | Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27 | 3.5 | 9 |
| 88 | Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. <i>Journal of the Neurological Sciences</i> , 2014 , 347, 229-34 | 3.2 | 8 |
| 87 | Patients Stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis. <i>European Neurology</i> , 2009 , 61, 278-84 | 2.1 | 8 |
| 86 | Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1398-1407 | 17.2 | 8 |

| | | | |
|----|--|------|---|
| 85 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756 | 11.2 | 8 |
| 84 | Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021 , | 6.5 | 8 |
| 83 | Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019 , 26, 363-370 | 6 | 8 |
| 82 | Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021 , 357, 577627 | 3.5 | 8 |
| 81 | Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. <i>European Journal of Neurology</i> , 2018 , 25, 739-746 | 6 | 7 |
| 80 | Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019 , 10, 820 | 4.1 | 7 |
| 79 | Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 32-40 | 4 | 7 |
| 78 | Interferon- β azathioprine as add-on therapies in patients with active multiple sclerosis. <i>Neurological Research</i> , 2012 , 34, 923-30 | 2.7 | 7 |
| 77 | Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2823-32 | 2.5 | 7 |
| 76 | Aggressive multiple sclerosis-is there a role for stem cell transplantation?. <i>Journal of Neurology</i> , 2005 , 252 Suppl 3, iii34-iii37 | 5.5 | 7 |
| 75 | Increased serum levels of C21 steroids in female patients with multiple sclerosis. <i>Physiological Research</i> , 2015 , 64, S247-54 | 2.1 | 7 |
| 74 | Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 412-5 | 6 | 7 |
| 73 | Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595 | 5 | 6 |
| 72 | Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S42-8 | 2 | 6 |
| 71 | Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , 2013 , 2013, 231345 | 1.1 | 6 |
| 70 | Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2021 , | 6 | 6 |
| 69 | Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015 , 37, 2543-51 | 3.5 | 5 |
| 68 | Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. <i>BMC Neurology</i> , 2017 , 17, 145 | 3.1 | 5 |

| | | | |
|----|--|-----|---|
| 67 | Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2018 , 388, 87-93 | 3.2 | 5 |
| 66 | Leukocyte counts in cerebrospinal fluid and blood following finteagrast treatment in subjects with relapsing forms of multiple sclerosis. <i>European Journal of Neurology</i> , 2013 , 20, 1032-42 | 6 | 5 |
| 65 | Natalizumab in the treatment of patients with multiple sclerosis: first experience. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 465-73 | 6.5 | 5 |
| 64 | The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102534 | 4 | 5 |
| 63 | Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018 , 84, 958-959 | 9.4 | 5 |
| 62 | Real-Life Outcome in Multiple Sclerosis in the Czech Republic. <i>Multiple Sclerosis International</i> , 2019 , 2019, 7290285 | 1.1 | 4 |
| 61 | Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020 , 9, 443-457 | 4.6 | 4 |
| 60 | The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 328-337 | 2.8 | 4 |
| 59 | Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 108-11 | 5 | 4 |
| 58 | Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study (S01.003). <i>Neurology</i> , 2012 , 78, S01.003-S01.003 | 6.5 | 4 |
| 57 | Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1 | 5.5 | 4 |
| 56 | Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020 , 267, 2851-2864 | 5.5 | 4 |
| 55 | Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 675-684.e2 | 4.9 | 4 |
| 54 | Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021 , 12, 554375 | 4.1 | 4 |
| 53 | Biofeedback Based Home Balance Training can Improve Balance but Not Gait in People with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2019 , 2019, 2854130 | 1.1 | 4 |
| 52 | Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021 , 31, 401-407.8 | 7.8 | 4 |
| 51 | Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?. <i>Journal of Neural Transmission</i> , 2019 , 126, 731-737 | 4.3 | 3 |
| 50 | Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. <i>International Journal of Neuroscience</i> , 2020 , 1-11 | 2 | 3 |

| | | | |
|----|--|------|---|
| 49 | Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8, | 9.1 | 3 |
| 48 | Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844 | 4 | 3 |
| 47 | Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e869-e880 | 6.5 | 3 |
| 46 | Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 755-766 | 5 | 3 |
| 45 | Do eyes with and without optic neuritis in multiple sclerosis age equally?. <i>Neuropsychiatric Disease and Treatment</i> , 2018 , 14, 2281-2285 | 3.1 | 3 |
| 44 | The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012 | 4 | 3 |
| 43 | Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1883-1891 | 5 | 2 |
| 42 | MENACTRIMS congress 2016. <i>Multiple Sclerosis Journal</i> , 2016 , 22, NP1-NP24 | 5 | 2 |
| 41 | Oral BG-12 in multiple sclerosis. <i>New England Journal of Medicine</i> , 2013 , 368, 1652-3 | 59.2 | 2 |
| 40 | Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: yes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1209-10 | 5 | 2 |
| 39 | Atrophy of caudate nucleus in Huntington® disease measured by computed tomography. <i>Journal of Neurology</i> , 2000 , 247, 880-1 | 5.5 | 2 |
| 38 | Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2001-2013 | 5 | 2 |
| 37 | Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021 , 96, e214-e227 | 6.5 | 2 |
| 36 | Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420975223 | 6.6 | 2 |
| 35 | The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482 | 5 | 2 |
| 34 | Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851 | 5 | 2 |
| 33 | Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021 , 208, 106180 | 6.9 | 2 |
| 32 | MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients. <i>Brain and Behavior</i> , 2017 , 7, e00644 | 3.4 | 1 |

| | | | |
|----|---|-----|---|
| 31 | DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.47-e1 | 5.5 | 1 |
| 30 | Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy. <i>Journal of Neuroimmunology</i> , 2014 , 275, 63-64 | 3.5 | 1 |
| 29 | PO129 Neda analysis by epoch in the opera studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A46.2-A46 | 5.5 | 1 |
| 28 | MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, e4.23-e4 | 5.5 | 1 |
| 27 | Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103389 | 4 | 1 |
| 26 | Early clinical markers of aggressive multiple sclerosis | | 1 |
| 25 | Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years | | 1 |
| 24 | Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. <i>Diagnostics</i> , 2021 , 11, | 3.8 | 1 |
| 23 | The clinical and paraclinical correlates of employment status in multiple sclerosis. <i>Neurological Sciences</i> , 2021 , 1 | 3.5 | 1 |
| 22 | Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232 | 6.7 | 1 |
| 21 | Steroid Sulfation in Neurodegenerative Diseases.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 839887 | 5.6 | 1 |
| 20 | Multiple Sclerosis Relapses Following Cessation of Fingolimod.. <i>Clinical Drug Investigation</i> , 2022 , 42, 3553.2 | 3.2 | 1 |
| 19 | Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061335 | 5.1 | 1 |
| 18 | Periventricular gradient of T tissue alterations in multiple sclerosis.. <i>NeuroImage: Clinical</i> , 2022 , 34, 103099 | 3.9 | 1 |
| 17 | Symptoms and diagnosis of multiple sclerosis 2013 , 36-48 | | 0 |
| 16 | Time course of lesion-induced atrophy in multiple sclerosis.. <i>Journal of Neurology</i> , 2022 , 1 | 5.5 | 0 |
| 15 | Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2832 | 5.1 | 0 |
| 14 | Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 166 | 4 | |

| | | |
|----|---|-----|
| 13 | ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.30-e1 | 5.5 |
| 12 | DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, e1.48-e1 | 5.5 |
| 11 | timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, e1.11-e1 | 5.5 |
| 10 | PO114 Neda achievement by time interval with daclizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, A42.1-A42 | 5.5 |
| 9 | ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, e4.9-e4 | 5.5 |
| 8 | Myelin basic protein in multiple sclerosis and other neurological disorders. <i>Journal of Neurology</i> , 2003 , 250, 874-5 | 5.5 |
| 7 | Immunoablative Therapy with Autologous Stem Cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis.. <i>Blood</i> , 2005 , 106, 5519-5519 | 2.2 |
| 6 | Regulation of heme degradation in association with multiple sclerosis. <i>FASEB Journal</i> , 2008 , 22, 1013.3 | 0.9 |
| 5 | Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN- β <i>PLoS ONE</i> , 2017 , 12, e0169957 | 3.7 |
| 4 | 060 Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A25.1-A25 | 5.5 |
| 3 | 044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A18.2-A19 | 5.5 |
| 2 | Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 55, 103187 | 4 |
| 1 | Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. <i>Pharmacoeconomics</i> , 2021 , 40, 323 | 4.4 |